This document summarizes key findings from the Disease Transmission Advisory Committee (DTAC) regarding donor-derived disease transmission through organ transplantation in the United States. DTAC has reviewed over 300 potential transmission cases reported from 2005 to 2010. Lessons learned include that bacterial and fungal transmissions are underrecognized, communications and recognition of donor-derived disease transmission can be improved, and screening and management of increased risk donors varies. The document emphasizes the delicate balance between organ availability and ensuring patient safety in transplantation.
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'Fundación Ramón Areces
Los días 15 y 16 de octubre de 2014, la Fundación Ramón Areces y la Real Academia Nacional de Farmacia, en colaboración con la Fundación de la Innovación Bankinter, reunieron en Madrid a algunos de los mayores expertos mundiales en nuevas terapias contra el cáncer. El Simposio Internacional, coordinado por la profesora y académica María José Alonso, analizó el momento actual de la lucha contra esta enfermedad. También fue un punto de encuentro para científicos de los más innovadores institutos de investigación en oncología, quienes debatieron sobre tres grandes temas: la Medicina Personalizada contra el cáncer, los nanomedicamentos en la terapia del cáncer y las terapias basadas en la inmunomodulación.
Circulating Tumor Cells (CTC) and pathological Complete Response (pCR) are strong independent prognostic factors in Inflammatory Breast Cancer (IBC) in a pooled analysis of two multicentre phase II trials (BEVERLY 1 & 2) of neoadjuvant chemotherapy combined with bevacizumab
The OncoScan(TM) platform for analysis of copy number and somatic mutations i...Lawrence Greenfield
The OncoScan microarray offers high-quality copy number, genotype, and somatic mutation data with whole-genome coverage and high resolution in cancer genes for use with challenging FFPE samples.
Serum long noncoding RNA Urothelial Carcinoma Associated 1: A novel biomarker...Ilika Kaushik
Zhi-kun Zheng, Cui Pang, Yang Yang,
Qiong Duan, Ju Zhang and Wen-chao Liu (2018). Journal of International Medical Research;
4:(1) 348-356
Molecular Diagnostics
Vassili Soumelis - Programme d’analyse globale et intégrative du micro-enviro...SiRIC_Curie
Programme d’analyse globale et intégrative du
micro-environnement tumoral - Vassili SOUMELIS, MD, PhD
Laboratoire d’Immunologie Clinique et Inserm U932
Clinical Genomics for Personalized Cancer Medicine: Recent Advances, Challeng...Yoon Sup Choi
I reviewed recent advances, challenges, and opportunities to implement clinical cancer genomics. Case studies of advanced systems, such as Foundation Medicine, MI-ONCOSEQ are introduced for benchmark. A few fundamental limitations to establish personalized oncology are also discussed.
In this OncomineWorld 2021 presentation, learn how next-generation sequencing is playing a crucial role in cancer research. To watch the full presentation, visit www.oncomine.com/events.
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'Fundación Ramón Areces
Los días 15 y 16 de octubre de 2014, la Fundación Ramón Areces y la Real Academia Nacional de Farmacia, en colaboración con la Fundación de la Innovación Bankinter, reunieron en Madrid a algunos de los mayores expertos mundiales en nuevas terapias contra el cáncer. El Simposio Internacional, coordinado por la profesora y académica María José Alonso, analizó el momento actual de la lucha contra esta enfermedad. También fue un punto de encuentro para científicos de los más innovadores institutos de investigación en oncología, quienes debatieron sobre tres grandes temas: la Medicina Personalizada contra el cáncer, los nanomedicamentos en la terapia del cáncer y las terapias basadas en la inmunomodulación.
Circulating Tumor Cells (CTC) and pathological Complete Response (pCR) are strong independent prognostic factors in Inflammatory Breast Cancer (IBC) in a pooled analysis of two multicentre phase II trials (BEVERLY 1 & 2) of neoadjuvant chemotherapy combined with bevacizumab
The OncoScan(TM) platform for analysis of copy number and somatic mutations i...Lawrence Greenfield
The OncoScan microarray offers high-quality copy number, genotype, and somatic mutation data with whole-genome coverage and high resolution in cancer genes for use with challenging FFPE samples.
Serum long noncoding RNA Urothelial Carcinoma Associated 1: A novel biomarker...Ilika Kaushik
Zhi-kun Zheng, Cui Pang, Yang Yang,
Qiong Duan, Ju Zhang and Wen-chao Liu (2018). Journal of International Medical Research;
4:(1) 348-356
Molecular Diagnostics
Vassili Soumelis - Programme d’analyse globale et intégrative du micro-enviro...SiRIC_Curie
Programme d’analyse globale et intégrative du
micro-environnement tumoral - Vassili SOUMELIS, MD, PhD
Laboratoire d’Immunologie Clinique et Inserm U932
Clinical Genomics for Personalized Cancer Medicine: Recent Advances, Challeng...Yoon Sup Choi
I reviewed recent advances, challenges, and opportunities to implement clinical cancer genomics. Case studies of advanced systems, such as Foundation Medicine, MI-ONCOSEQ are introduced for benchmark. A few fundamental limitations to establish personalized oncology are also discussed.
In this OncomineWorld 2021 presentation, learn how next-generation sequencing is playing a crucial role in cancer research. To watch the full presentation, visit www.oncomine.com/events.
The Presence and Persistence of Resistant and Stem Cell-Like Tumor Cells as a...QIAGEN
Epithelial ovarian cancer is the fifth leading cause of cancer-related deaths of women in the United States and Europe and ranks as the second most common type of gynecological malignancy. Most cases are diagnosed in advanced stages and although the response rates to platinum-based chemotherapy are high, the majority of patients nevertheless have poor survival rates. Although the reasons for these poor outcomes are likely to be multifactorial, one particular area of interest has recently focused on hematogenous tumor cell dissemination that has been shown to originate from disseminated tumor cells (DTCs) in the bone marrow (BM) and circulating tumor cells (CTCs) in the blood. Here, we demonstrate that the negative prognostic impact of CTCs and DTCs arise from specific cellular phenotypes and are associated with platinum-resistance and stem cell-associated proteins.
In this presentation we showcase the latest advancements in myeloid genomic profiling: The Ion Torrent Oncomine Myeloid Assay GX.
Learn how this solution addresses key challenges in myeloid molecular testing and see recent data from the University of Pennsylvania.
Learn more at www.oncomine.com/myeloid
Suresh S. Ramalingam, MD, FACP, FASCO, Alexander Drilon, MD, and John Heymach, MD, PhD, prepared useful Practice Aids pertaining to lung cancer for this CME/MOC activity titled "Everything You Need to Know About Molecular Testing and Targeted Therapies in NSCLC: Essential Guidance for Modern Patient-Centered Precision Lung Cancer Care." For the full presentation, complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/2IIiRzP. CME/MOC credit will be available until November 29, 2021.
Maria Arcila, MD, Zofia Piotrowska, MD, and Joshua Bauml, MD, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/CC activity titled “New Horizons in EGFR-Mutated NSCLC: Broadening the Impact of Precision Testing in the Context of an Expanding Treatment Landscape.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CC information, and to apply for credit, please visit us at https://bit.ly/3kH1ygr. CME/MOC/CC credit will be available until January 25, 2022.
Step by Step, from Liquid Biopsy to a Genomic Biomarker: Liquid Biopsy Series...QIAGEN
Liquid biopsies enable us to monitor the evolution of genetic aberrations in primary tumors as they shed the tumor cells into the circulation. The limitation is the ability to detect these low frequency genetic aberrations in a consistent manner to understand short- and long-term implications and how this information will be used in the clinic. This slidedeck will cover the challenges and solutions associated with multiple steps as one starts with liquid biopsy and move towards finding a new biomarker.
Quantification of Somatic Chromosomal Rearrangements in Circulating Cell- Fre...Laura Berry
Presented at the 3rd qPCR and Digital PCR Congress: USA. To find out more, visit:
www.global-engage.com
George Vasmatzis, Co-director of the Biomarker Discovery Program at Mayo Clinic, discusses identifying new ways to monitor and treat recurrence of cancer using liquid biopsies from blood tests.
David R. Jones, MD, and Roy S. Herbst, MD, PhD, prepared useful practice aids pertaining to lung cancer for this CME activity titled "Turning Tides in Targeted Therapy for Early-Stage EGFR-Mutated NSCLC: Latest Data and Practical Guidance for Thoracic Surgeons and the Multidisciplinary Team on the Emerging Role of EGFR-Targeted Therapy in Resectable Lung Cancer." For the full presentation, complete CME information, and to apply for credit, please visit us at https://bit.ly/2PSVELG. CME credit will be available until November 9, 2021.
Two new drugs for colorectal cancer may offer new hope for late stage patients, and they might hit the market in 2013.
Dr. Rich Goldberg, physician-in-chief of the Ohio State University Medical Center and a leader in colorectal cancer research is going to give you the straight facts about these drugs:
* What hope might they offer?
* What side effects do they cause?
* Will either be the right drug for you?
About Dr. Goldberg:
Dr. Richard Goldberg is an internationally renowned gastrointestinal oncologist and the physician-in-chief at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Institute (OSUCCC-James). He is a member and former chair of the National Cancer Institute Colorectal Task Force and an international leader in evaluating new agents for the treatment of colorectal cancer and researching inherited colorectal cancer syndromes
Organ-i World Transplant Congress Soild Organ Rejection Test (k-SORT)Kevin Jaglinski
SORT
Solid Organ Rejection Test is a gene based biomarker panel that evaluates the gene expression profile of RNA isolated from peripheral blood leukocytes. SORT is intended for diagnosis and subsequent monitoring of renal transplant recipients who have a high probability of early cellular or humoral acute rejection at the time of testing. SORT should be utilized in conjunction with standard clinical assessment.
The renal transplant community is heavily reliant on serum creatinine levels as a trigger to diagnose acute rejection. However, serum creatinine is a late indicator of renal injury and exhibits high variability and high false positivity. These inadequacies lead to delayed diagnosis and irreversible renal damage.
As such, we developed the World’s first predictive test of acute rejection. This solid organ rejection test (SORT) accurately detects acute rejection 4 months prior to biopsy or other signs of clinical graft dysfunction.
SORT is intended to be utilized in conjunction with standard clinical assessment.
In the US for 0.5 Million patients with Renal Failure, transplant is the treatment of choice, but due to a critical shortage of organs, there are 85,000 patients on the waitlist of 2.5 years. Only 21,000 receive kidney transplants annually. This costs Medicare $6.3 Billion. The absence of accurate, non-invasive monitoring tests is an unmet need reflected in the high attrition rates. Organ-I is commercializing, ‘SORT’ (Solid Organ Rejection Test) first predictive, accurate, non-invasive test available to patients, averting the need for unnecessary biopsies and saving upwards of $750M.
The Presence and Persistence of Resistant and Stem Cell-Like Tumor Cells as a...QIAGEN
Epithelial ovarian cancer is the fifth leading cause of cancer-related deaths of women in the United States and Europe and ranks as the second most common type of gynecological malignancy. Most cases are diagnosed in advanced stages and although the response rates to platinum-based chemotherapy are high, the majority of patients nevertheless have poor survival rates. Although the reasons for these poor outcomes are likely to be multifactorial, one particular area of interest has recently focused on hematogenous tumor cell dissemination that has been shown to originate from disseminated tumor cells (DTCs) in the bone marrow (BM) and circulating tumor cells (CTCs) in the blood. Here, we demonstrate that the negative prognostic impact of CTCs and DTCs arise from specific cellular phenotypes and are associated with platinum-resistance and stem cell-associated proteins.
In this presentation we showcase the latest advancements in myeloid genomic profiling: The Ion Torrent Oncomine Myeloid Assay GX.
Learn how this solution addresses key challenges in myeloid molecular testing and see recent data from the University of Pennsylvania.
Learn more at www.oncomine.com/myeloid
Suresh S. Ramalingam, MD, FACP, FASCO, Alexander Drilon, MD, and John Heymach, MD, PhD, prepared useful Practice Aids pertaining to lung cancer for this CME/MOC activity titled "Everything You Need to Know About Molecular Testing and Targeted Therapies in NSCLC: Essential Guidance for Modern Patient-Centered Precision Lung Cancer Care." For the full presentation, complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/2IIiRzP. CME/MOC credit will be available until November 29, 2021.
Maria Arcila, MD, Zofia Piotrowska, MD, and Joshua Bauml, MD, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/CC activity titled “New Horizons in EGFR-Mutated NSCLC: Broadening the Impact of Precision Testing in the Context of an Expanding Treatment Landscape.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CC information, and to apply for credit, please visit us at https://bit.ly/3kH1ygr. CME/MOC/CC credit will be available until January 25, 2022.
Step by Step, from Liquid Biopsy to a Genomic Biomarker: Liquid Biopsy Series...QIAGEN
Liquid biopsies enable us to monitor the evolution of genetic aberrations in primary tumors as they shed the tumor cells into the circulation. The limitation is the ability to detect these low frequency genetic aberrations in a consistent manner to understand short- and long-term implications and how this information will be used in the clinic. This slidedeck will cover the challenges and solutions associated with multiple steps as one starts with liquid biopsy and move towards finding a new biomarker.
Quantification of Somatic Chromosomal Rearrangements in Circulating Cell- Fre...Laura Berry
Presented at the 3rd qPCR and Digital PCR Congress: USA. To find out more, visit:
www.global-engage.com
George Vasmatzis, Co-director of the Biomarker Discovery Program at Mayo Clinic, discusses identifying new ways to monitor and treat recurrence of cancer using liquid biopsies from blood tests.
David R. Jones, MD, and Roy S. Herbst, MD, PhD, prepared useful practice aids pertaining to lung cancer for this CME activity titled "Turning Tides in Targeted Therapy for Early-Stage EGFR-Mutated NSCLC: Latest Data and Practical Guidance for Thoracic Surgeons and the Multidisciplinary Team on the Emerging Role of EGFR-Targeted Therapy in Resectable Lung Cancer." For the full presentation, complete CME information, and to apply for credit, please visit us at https://bit.ly/2PSVELG. CME credit will be available until November 9, 2021.
Two new drugs for colorectal cancer may offer new hope for late stage patients, and they might hit the market in 2013.
Dr. Rich Goldberg, physician-in-chief of the Ohio State University Medical Center and a leader in colorectal cancer research is going to give you the straight facts about these drugs:
* What hope might they offer?
* What side effects do they cause?
* Will either be the right drug for you?
About Dr. Goldberg:
Dr. Richard Goldberg is an internationally renowned gastrointestinal oncologist and the physician-in-chief at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Institute (OSUCCC-James). He is a member and former chair of the National Cancer Institute Colorectal Task Force and an international leader in evaluating new agents for the treatment of colorectal cancer and researching inherited colorectal cancer syndromes
Organ-i World Transplant Congress Soild Organ Rejection Test (k-SORT)Kevin Jaglinski
SORT
Solid Organ Rejection Test is a gene based biomarker panel that evaluates the gene expression profile of RNA isolated from peripheral blood leukocytes. SORT is intended for diagnosis and subsequent monitoring of renal transplant recipients who have a high probability of early cellular or humoral acute rejection at the time of testing. SORT should be utilized in conjunction with standard clinical assessment.
The renal transplant community is heavily reliant on serum creatinine levels as a trigger to diagnose acute rejection. However, serum creatinine is a late indicator of renal injury and exhibits high variability and high false positivity. These inadequacies lead to delayed diagnosis and irreversible renal damage.
As such, we developed the World’s first predictive test of acute rejection. This solid organ rejection test (SORT) accurately detects acute rejection 4 months prior to biopsy or other signs of clinical graft dysfunction.
SORT is intended to be utilized in conjunction with standard clinical assessment.
In the US for 0.5 Million patients with Renal Failure, transplant is the treatment of choice, but due to a critical shortage of organs, there are 85,000 patients on the waitlist of 2.5 years. Only 21,000 receive kidney transplants annually. This costs Medicare $6.3 Billion. The absence of accurate, non-invasive monitoring tests is an unmet need reflected in the high attrition rates. Organ-I is commercializing, ‘SORT’ (Solid Organ Rejection Test) first predictive, accurate, non-invasive test available to patients, averting the need for unnecessary biopsies and saving upwards of $750M.
El "incipiente" mercado relacionado con el uso de drones está capacitado para generar oportunidades de negocio por un valor total de 127.300 millones de dólares (111.846 millones de euros), donde las infraestructuras, la agricultura y el transporte serían los sectores más beneficiados.
Challenges and Opportunities for Digital PCR in the CLIA Laboratory of the Mo...Kate Barlow
Anthony Magliocco, Chair of Anatomical Pathology, Moffitt Cancer Center, USA
The Moffit Cancer Center is one of the largest NCI designated comprehensive free-standing cancer centers in the USA. The center has developed one of the most advanced personalized cancer medicine treatment programs in the world. This program is supported by a comprehensive and advanced CLIA molecular diagnostics. Digital PCR assays are currently being developed for several clinical applications including TKI resistance monitoring in patients with advanced lung cancer. The challenges and opportunities in deploying digital PCR into clinical practice will be discussed.
NeoGenomics is a fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals. This is August 2014 Company Overview Presentation.
Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...Andrew Aijian
Analysis and synthesis of a pulse survey conducted across >140 oncologists, pathologists, and lab directors regarding current adoption and trends associated with emerging oncology biomarkers and companion diagnostics (CDx), with an emphasis on next-generation sequencing (NGS)-based CDx.
Merkel Cell Carcinoma: From Diagnosis to Treatment (webinar)Natalie Richardson
Merkel Cell Carcinoma: From Diagnosis to Treatment ~ view the webinar recording on our youTube channel: https://youtu.be/vIcrzSTabKw
Hear Dr. Marco Iafolla, Medical Oncologist at William Osler Health System, review the latest news, clinical data and other updates as they relate to the treatment of merkel cell carcinoma (MCC). Dr. Iafolla provides an update on the science behind primary and metastatic MCC diagnosis, an overview of the disease features, staging and prognostication, surgery and treatment options including immuno-oncology for MCC, and the impact of all of this to patients. (Rec. Nov. 27, 2019)
Has cancer science got you stumped and overwhelmed? Leading gynecologic oncologist, Dr. Don Dizon, takes us to cancer college in this webinar. He explains the science behind ovarian cancer, how it develops, how it's diagnosed, and how ovarian cancer treatments work.
Steve Rozen's keynote talk at IEEE CIBCB 2016
Big Genome Data Sheds Light on Cancer Causes
Steven G. Rozen, PhD
Professor, Cancer & Stem Cell Programme, Duke-NUS Medical School, Singapore
Director, Duke-NUS Centre for Computational Biology
The last eight years have see a revolution in the availability of DNA sequencing data. This revolution has been driven by costs that have plummeted from US$ 10 million per human genome in 2008 to US $1,200 today. Abundant sequencing data brings with it a previously unimaginable range of research possibilities in all areas of biomedical research. Naturally, these research possibilities make heavy demands on computation and data storage, because costs of sequencing are falling much faster than Moore's law. In this talk I will present a high level overview of these computational demands. I will then go into detail on a few of the cancer-related big data projects my lab is working on. One of these is "mutation signature analysis", which has important applications in cancer prevention and epidemiology and in research into the fundamental processes by which cancers arise. One example of the importance of this approach is the recent finding that a highly mutagenic herbal remedy is implicated in many more geographical regions and types of cancer than suspected a few years ago.
Confronting the Challenges of HIV Care in an Aging Population.2019hivlifeinfo
Еxpert faculty use case-based examples to examine considerations for aging patients with HIV. Topics include ART modification, bone loss, renal impairment, cardiovascular risk, and cognitive decline.
This slide deck has been created for clinician use in creating presentations detailing Colorectal Cancer Liver Metastases, the Selective Internal Radiation Therapy (SIRT) procedure available to treat this condition, supported by the clinical data that supports this treatment and and ongoing RCT trials to further document the success of this treatment. This information maybe used in its entirety or in sections, according to the material being presented and the audience to which it will be used. The sections included in this slide deck are as follows:
Colorectal Cancer Liver Metastases (mCRC)
Overview Selective Internal Radiation Therapy (SIRT)
Overview SIR-Spheres(r) microspheres
Clinical Data in mCRC Ongoing Level 1 RCT for mCRC in the liver
Overcoming the challenges of molecular diagnostics in government health insti...Yakubu Sunday Bot
overcoming the challenges of molecular diagnostics in government owned health institution in nigeria.Several challenges abound in the Nigerian health sector ranging from financial,political and lack of commitment.Its obvious and no wonder the state of health care deliveryy, vis a vis its quality of care to its citizenry.
Development and Clinical Validation of Liquid ddPCR Tests for Actionable Soma...Kate Barlow
We have developed and validated blood-based variant specific ddPCR tests for EGFR, KRAS, BRAF, EML4-ALK, ROS1 and RET variants. These tests are intended for use in patients diagnosed with Non-Small Cell Lung Cancer (NSCLC). The tests have been on the market as ”the GeneStrat® test” since 2015; and in that time, has been utilized to analyze over 80,000 individual variants. Greater than 90% of tests have been delivered in less than 72 hours from receipt at the testing Laboratory. We will report on factors critical to the development, validation and on-market support of these tests. In this talk we will cover:
• Learning how Droplet Digital ™ PCR technology is being used for liquid biopsy testing in the clinical setting
• Reviewing development and validation case studies for cfDNA testing using ddPCR
• Reviewing performance data and quality metrics from on-market experiences
Gary Pestano, Vice President, Development and Operations, Biodesix
Is insourcing NGS testing worth it?
Dartmouth-Hitchcock has experienced nearly 40% savings by bringing NGS testing in-house. A recent AMP study using non-small cell lung cancer as an example cites $2.7 million in anticipated savings.
In-house NGS testing is the foundation of any modern precision medicine program. It can have a profound effect on patient care. And, as these examples show, a strong business case can be made.
How have Dartmouth-Hitchcock and other progressive institutions been so successful despite myriad challenges?
Join us for a webinar on May 31st at 12pm ET as Eric Loo, MD (Dartmouth-Hitchcock) and Rakesh Nagarajan, MD, PhD (PierianDx) explore answers to this question and more.
In this webinar you will learn:
How recent precision medicine trends are driving strong market growth for clinical NGS and other complex molecular testing.
How to make a strong business case for in-house NGS testing.
Challenges your institution is likely to face by insourcing.
Blueprints for overcoming these challenges, including reimbursement.
21st Century Pharmacare to Optimize Access to 21st Century Therapies
Panel B: Not-so-Rare Therapies (Yesterday, Today, Tomorrow)
Moderator: Durhane Wong-Rieger, CORD
Panelists: Lisa Machado, Canadian CML Network; Jim Whitlock, The Hospital for Sick Children; John Kuruvilla, Princess Margaret Hospital; Aleksandar Ivovic, Diabetes Patient Advocate; Joanne Lewis, Diabetes Canada; Louise Binder, HIV Patient Advocate; Nancy Durand, Sunnybrook Health Sciences Centre
Similar to Michael Ison USA - Monday 28 - Traceability and Biovigilance (20)
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Michael Ison USA - Monday 28 - Traceability and Biovigilance
1. An Update on Donor-Derived
Disease Transmission Through
Organ Transplantation in the USA
Michael G. Ison, MD MS
Associate Professor
Divisions of Infectious Diseases & Organ Transplantation
2011 Organ Donation Congress – Buenos Aires, Argentina
2. Disclosures
• Research Support°
ADMA, Adamas, BioCryst, Chimerix, GlaxoSmithKline, Roche,
ViraCor*
• Paid Consultation
Abbott, Abbott Molecular*, Astellas*, Biogen Idec, Crucell, ViraCor*
• Unpaid Consultation
BioCryst, Biota, Cellex, Clarassance, GlaxoSmithKline, MP
Bioscience*, NexBio, Roche, Toyama, T2 Diagnostics*
• Data & Safety Monitoring Board Participation
Chimerix, NexBio
As of 11/22/11; °Paid to Northwestern University; *Related to topic.
3. Acknowledgments
DTAC data was supported wholly or in part
by Health Resources and Services
Administration contract 234-2005- 370011C.
The content is the responsibility of the
authors alone and does not necessarily
reflect the views or policies of the
Department of Health and Human Services,
nor does mention of trade names,
commercial products, or organizations imply
endorsement by the U.S. Government.
4. Case 1: Something Rare?
• 54 yo WM with HBV/HCV/HCC
• Day 5: Fever to 102.4, mild frontal HA since Tx
• IS: ATG, Tacrolimus, Azathioprine
• Abx: Pip-Tazo, HBIg, 3TC, Famciclovir, TMP-SMX
• SH: Suburbs, Iron worker
• PE: Non-focal except for a tender RUE
peripheral IV catheter
5. Case 1: Something Rare?
• Continued with fever, LFTs increased
• Seizure (? Hypoxemic)
• Progressive “sepsis” with elevated
LFTs and renal dysfunction
• Call from another Transplant ID
doctor: “how is your recipient doing?”
7. Case 2: Something Common?
• Patient is a 56 yo WM
• Underwent OHT November 2005
Toxo D+/R–, CMV D+/R–
Pyramethamine-Sulfadiazine
Valganciclovir
• 9 Days Post-Transplant
Donor has + blood cultures drawn the day prior to donation
Positive for Pseudomonas aeruginosa
• What Went Right? What Went Wrong?
Took several days to convey results to recipient centers
Patient was receiving ciprofloxacin for a probable UTI, which
covered the bacteria with no serious sequellae
8. Case 3: Refocusing on Risk
• One recipient was identified with post-transplant
HCV & HIV infection with no obvious risk factors
and negative pre-transplant testing
• Reported to OPO, UNOS, and CDC
• Donor – Lookback Assessment
Negative serology for HIV & HCV
Appropriately labeled as “high risk” by PHS
Guidelines
Subsequent testing of post-transfusion serum was +
for HIV and HCV by PCR
• All other recipients tested + for HIV & HCV
Ison et al. Am J Transplant. 2011; 11: 1218–1225
9. Case 4: Living Donors Are Not Immune
MMWR. 2011; 60: 297-301.
10. Unique Features of Organ Procurement
• Restricted timeline (typically 24 hours)
• Different Screening Paradigm - Not “Zero Risk”
• Donor History
Second Hand Story
Lack of Standardization
Incomplete Data Collection
• Serology-based Screening
• Variable NAT capacity and practice
Ison et al. Am J Transplant. 2009; 9: 1929-1935. Ison & Nalesnik. Am J Transplant. 2011; 11: 1123–1130.
11. A Significant Organ Shortage Exists
2009 DATA
Organ Transplants 28,465
Waitlist Candidates 105,567
Deaths on Waitlist 9,848
*Waiting list deaths includes removals for death, too sick to transplant, and those non-transplanted removals identified to have died within
seven days of removal from linkage to SSDMF data. Based on OPTN data as of April 16, 2010.
13. Current US Donor-Derived Disease Policy
• Policy 2: Focused on Donor Screening
Review of donor medical/social history
Defines donors at increased risk of transmitting infections
Defines required donor screening (serologic)
• Policy 4: Focused on recognizing and reporting
disease transmission
Requirement to inform recipients of new data relative to risk
„When a transplant program is informed that an organ recipient at that
program is confirmed positive for or has died from a transmissible
disease or medical condition for which there is substantial concern that
it could be from donor origin, the transplant program must notify by
phone and provide available documentation, as soon as possible and
not to exceed one complete working day, to the procuring OPO‟
Patient Safety Contact (required for each OPO and TC)
http://optn.transplant.hrsa.gov/policiesAndBylaws/policies.asp
14. Disease Transmission Advisory Committee
• Workflow
Report made to Patient Safety Staff
o Prepare summary of event
o Redact identifiers
o Upload key materials to SharePoint Server
E-mail based discussion
o Initial e-mail sent to all members
o Ongoing electronic discussion
Day 45 Follow-up Reports submitted
Special Cases
o Reportable Diseases: Inform CDC
o Event-Specific Conference Calls
Monthly Conference Calls & Bi-Annual Meetings
Ison et al. Am J Transplant. 2009; 9: 1929-1935.
15. DTAC Members as of July 2011
Dr. Emily Blumberg, Chair (TID) Dr. Michael Green, Vice Chair (Peds TID)
Ms. Carrie Comellas (TX Coordinator) Dr. Edward Dominguez (TID)
Dr. Afshin Ehsan (Thoracic TX Surgeon) Mr. Barry Friedman (TX Administrator)
Dr. Thomas Gross (Oncology) Dr. Daniel Kaul (TID)
Dr. Simone Kushne (TID) Dr. G. Marshall Lyon (TID)
Dr. Rachel Miller (TID) Ms. Samantha Mitchell (OPO)
Dr. Michael Nalesnik (Pathology) Dr. Volker Nickeleit (Pathology)
Dr. Timothy Pruett (Abd TX Surgeon) Dr. Phillip Ruiz (Pathology)
Dr. Michael Souter (Tx Anesthesiology) Ms. Linda Weiss (Dir of OPO Lab Services)
Dr. Betsy Tuttle Newhall (Abd TX Surgeon) Dr. Russell Wiesner (Hepatology)
Dr. Jim Bowman (Ex Officio, HRSA) Dr. Bernard Kozlovsky (Ex Officio, HRSA)
Ms Raelene Skerda (Ex Officio, HRSA)
OPTN Staff: Shandie Covington, Robert Metzger, MD, Kimberly Parker,
Sarah Taranto, Kimberly Taylor, RN
OPTN
16. Potential Disease Transmission Cases
Reported to DTAC
200
176*
180
152 152
160
140
102
120
97
100
80
60
60
40
7
20
0
2005 2006 2007 2008 2009 2010 2011
OPTN *Estimated based on 161 reports through November 21, 2011.
17. Potential Disease Transmission Reports for
Deceased Donors 3/2006-12/2010 by
Donor Service Area (DSA)
Number of Donor Reports
1 DSA with
ZERO
reports
Individual DSAs
OPTN
18. Percent of Deceased Donors Recovered
2008-2009 Reported to DTAC by Region
OPTN
19. Potential Disease Transmission Reports for
Deceased Donors During 2010 by DSA
Number of Donor Reports
12 DSAs
with ZERO
reports
Individual DSAs
OPTN
22. Lessons Learned: DTAC Data
• Bacterial Transmissions
Likely under-recognized & under-reported
Often involves resistant bacteria
Follow-up of outstanding culture data
• Fungi
Endemic mycoses & Cryptococcus increasing
High morbidity and mortality
• Mycobacteria
• Parasites
Increase in Strongyloides, Chagas, & Amoeba
• Viral Transmissions
Increased recognition of PB19, LCMV
Need to use NAT to diagnose transmission, esp for HCV
Ison et al. Am J Transplant. 2009; 9: 1929-1935. Ison & Nalesnik. Am J Transplant. 2011; 11: 1123–1130.
23. Lessons Learned: DTAC Data
• Communications
Inefficient systems in place
Delays are common
• Poor systems for recognizing DDD
No cluster analysis
Severe outcomes not recognized by all recipient teams
Variable recognition and report
Management of positive cultures/result information locally
• Increased risk donors
Variable definitions used
Variable understanding of risk
Variable follow-up of recipients
• Living donors
Ison et al. Am J Transplant. 2009; 9: 1929-1935. Ison & Nalesnik. Am J Transplant. 2011; 11: 1123–1130.
24. Michael G. Ison, MD MS
Questions? 312-695-4186
mgison@northwestern.edu
I am a registered organ donor!
Are you?